| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
3 |
| Employees |
7 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-14 |
| Cash Flow (TTM) (Millions $) |
-11 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Neubase Therapeutics Inc. is a biotechnology company focused on developing and commercializing novel gene-targeted therapies for a range of diseases. The company's approach involves using its proprietary platform technology, called PATrOL™, to develop small, synthetic molecules that can modulate gene expression and correct the underlying genetic defects causing the diseases.
Neubase's innovative platform allows for the potential treatment of a wide variety of genetic diseases, including those that have been historically difficult to address using traditional gene therapies. The company's goal is to provide targeted and personalized therapies that can effectively treat genetic disorders and improve patient outcomes.
Neubase Therapeutics' pipeline includes several programs targeting specific genetic diseases, such as Huntington's disease and myotonic dystrophy. Through its research and development efforts, the company aims to advance these therapies towards clinical trials and eventual commercialization.
Overall, Neubase Therapeutics Inc. is dedicated to utilizing its novel gene-targeting platform to develop transformative therapies that have the potential to significantly impact the lives of patients with genetic diseases.
Company Address: 350 Technology Drive Pittsburgh 15219 PA
Company Phone Number: 763-3350 Stock Exchange / Ticker: NASDAQ NBSE
|
%
0.4% 